RU96113771A - IMMUNOGLOBULIN AGAINST EBOL FEVER FROM SERUM OF HORSE BLOOD, LIQUID (IMMUNOGLOBULIN EBOL) - Google Patents

IMMUNOGLOBULIN AGAINST EBOL FEVER FROM SERUM OF HORSE BLOOD, LIQUID (IMMUNOGLOBULIN EBOL)

Info

Publication number
RU96113771A
RU96113771A RU96113771/14A RU96113771A RU96113771A RU 96113771 A RU96113771 A RU 96113771A RU 96113771/14 A RU96113771/14 A RU 96113771/14A RU 96113771 A RU96113771 A RU 96113771A RU 96113771 A RU96113771 A RU 96113771A
Authority
RU
Russia
Prior art keywords
immunoglobulin
ebol
fever
liquid
serum
Prior art date
Application number
RU96113771/14A
Other languages
Russian (ru)
Other versions
RU2130318C1 (en
Inventor
В.В. Михайлов
И.В. Борисевич
Г.Д. Тиманькова
В.П. Краснянский
Н.В. Потрываева
Е.В. Лебединская
Н.К. Черникова
Original Assignee
Вирусологический центр научно-исследовательского института микробиологии МО РФ
Filing date
Publication date
Application filed by Вирусологический центр научно-исследовательского института микробиологии МО РФ filed Critical Вирусологический центр научно-исследовательского института микробиологии МО РФ
Priority to RU96113771A priority Critical patent/RU2130318C1/en
Priority claimed from RU96113771A external-priority patent/RU2130318C1/en
Publication of RU96113771A publication Critical patent/RU96113771A/en
Application granted granted Critical
Publication of RU2130318C1 publication Critical patent/RU2130318C1/en

Links

Claims (1)

1. Иммуноглобулин против лихорадки Эбола из сыворотки крови лошадей, жидкий (иммуноглобулин Эбола), обладающий вируснейтрализующей активностью к вирусу Эбола и используемый для экстренной профилактики лихорадки Эбола, отличающийся повышенным содержанием γ -глобулинов (от 90 до 98% от общего количества белка, от 0,081 до 0,110 г в 1 мл) и содержанием в нем альбумина , α- и β -глобулинов в количестве не более 10%, является 10%-ным раствором иммуноглобулинов сыворотки крови лошадей, содержащей антитела к вирусу Эбола, апирогенный, нетоксичный, стерильный.1. Immunoglobulin against Ebola fever from horse serum, liquid (Ebola immunoglobulin), which has virus-neutralizing activity against Ebola virus and used for emergency prevention of Ebola fever, characterized by an increased content of γ-globulins (from 90 to 98% of the total protein, from 0.081 up to 0.110 g in 1 ml) and its content of albumin, α- and β-globulins in an amount of not more than 10%, is a 10% solution of horse serum immunoglobulins containing antibodies to the Ebola virus, pyrogen-free, non-toxic, sterile.
RU96113771A 1996-07-05 1996-07-05 Preparation containing immunoglobulin against abol fever from horse blood serum and liquid abol immunoglobulin RU2130318C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU96113771A RU2130318C1 (en) 1996-07-05 1996-07-05 Preparation containing immunoglobulin against abol fever from horse blood serum and liquid abol immunoglobulin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU96113771A RU2130318C1 (en) 1996-07-05 1996-07-05 Preparation containing immunoglobulin against abol fever from horse blood serum and liquid abol immunoglobulin

Publications (2)

Publication Number Publication Date
RU96113771A true RU96113771A (en) 1998-10-27
RU2130318C1 RU2130318C1 (en) 1999-05-20

Family

ID=20182979

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96113771A RU2130318C1 (en) 1996-07-05 1996-07-05 Preparation containing immunoglobulin against abol fever from horse blood serum and liquid abol immunoglobulin

Country Status (1)

Country Link
RU (1) RU2130318C1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2578159C1 (en) * 2015-02-13 2016-03-20 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации" (ФГБУ "ФНИЦЭМ им. Н.Ф.Гамалеи" Минздрава России) Immunobiological agent and method for use thereof to induce specific immunity against ebola virus
RU2585695C1 (en) * 2015-03-12 2016-06-10 Закрытое акционерное общество "Вектор-Медика" (ЗАО "Вектор-Медика") Method of inhibiting infectious activity of ebola virus in experiment
RU2578160C1 (en) * 2015-03-31 2016-03-20 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации" (ФГБУ "ФНИЦЭМ им.Н.Ф.Гамалеи" Минздрава России) Immunobiological agent and method for use thereof to induce specific immunity against ebola virus (versions)
RU2646458C2 (en) * 2015-09-03 2018-03-05 Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации Device for mixing of immune blood serum with ethyl alcohol in cold
RU2627631C1 (en) * 2016-10-11 2017-08-09 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Method for production of hyperimmune serum containing heterologic immunoglobulines against ebola fever
RU2673546C1 (en) * 2017-08-10 2018-11-28 Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации Method for producing liquid immunoglobulin against ebola fever from horse blood serum

Similar Documents

Publication Publication Date Title
Gerin et al. Australia antigen: large-scale purification from human serum and biochemical studies of its proteins
Gotze et al. The C3-activator system: an alternate pathway of complement activation
Davis 3rd et al. Heterogeneity of nephritic factor and its identification as an immunoglobulin.
DE69032833D1 (en) DIAGNOSIS AND TREATMENT OF INSULIN-DEPENDENT DIABETES MELLITUS
RU93046317A (en) CHINDROITINASE, METHOD FOR ITS PREPARATION AND CONTENTS OF ITS PHARMACEUTICAL COMPOSITIONS
NO893373D0 (en) A HUMAN RHINO VIRUS RECEPTOR PROTEIN THAT INHIBITS VIRUS INFECTION.
DK0523395T3 (en) Seroreactive regions on proteins E1 and E2 in HPV 16
DK0413188T3 (en) Process for Preparation of Unmodified, Intravenously Administerable IgM and / or IgA-Containing Immunoglobulin Preparations
RU96113771A (en) IMMUNOGLOBULIN AGAINST EBOL FEVER FROM SERUM OF HORSE BLOOD, LIQUID (IMMUNOGLOBULIN EBOL)
Hyllseth et al. Neutralization of equine arteritis virus; enhancing effect of guinea pig serum
DE3887750D1 (en) SELECTIVE REMOVAL OF IMMUNE COMPLEXES.
Tissot et al. No evidence for protein modifications in fresh frozen plasma after photochemical treatment: an analysis by high‐resolution two‐dimensional electrophoresis
Ehrnst Complement activation by measles virus cytotoxic antibodies: Alternative pathway C activation by hemagglutination-inhibition antibodies but classical activation by hemolysin antibodies
Stevens et al. Immunochemical and electrophoretic properties of oestrous rabbit uterine fluid proteins obtained by uterine ligation
Albar et al. Structural requirements of rabbit IgG F (ab') 2 fragment for activation of the complement system through the alternative pathway—I. Disulfide bonds
Hardwicke et al. Human α1-glycoproteins Separation from pathological urine and examination by immunological and electrophoretic methods
Wilkerson et al. Anti‐A isoagglutinins in two blood type B cats are IgG and IgM
RO84706A (en) PROCESS FOR THE PREPARATION OF TRIPEPTIDES WITH N-CARBOOYALKYLPROLINE CONTENT
McLeod et al. Anti-MIF activity of serum from a rabbit immunized with human B-lymphoid cell line migration inhibitory factor
RU2003135173A (en) THE PRODUCT CONTAINING IMMUNOGLOBULIN AGAINST MARBURG FEVER FROM HORSE BLOOD SERUM LIQUID (IMMUNOGLOBULIN HORSE MARBURG)
ES524608A0 (en) COLLECTING SYSTEM OF BLOOD COMPONENTS, CONTINUOUS FLOW AND INCREASED PERFORMANCE.
Sasaki et al. The subcomponent C1q of the first component of guinea pig complement: Purification and characterization
FR2586813B1 (en) MODIFIED PROTEIN SUPPORTS SUITABLE FOR REVERSIBLE IMMOBILIZATION OF IMMUNOLOGICALLY ACTIVE ANTIBODIES OR SUBSTANCES, AND THEIR APPLICATIONS FOR THE DETERMINATION AND PURIFICATION OF ANTIGENS OR THE LIKE.
RU2089214C1 (en) Agent for decrease of vessel pathological permeability to proteins
RU94044991A (en) Method of preparing immunosorbent for viral hepatitis c immunodiagnosis